 BidaskClub lowered shares of Regeneron Pharmaceuticals NASDAQ:REGN from a buy rating to a hold rating in a research note released on Saturday morning, BidAskClub reports. Several other brokerages have also weighed in on REGN. Barclays upped their price objective on Regeneron Pharmaceuticals from 615.00 to 675.00 in a report on Thursday, August 6th. SVB Leerink ... 